Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

armasset.com">kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that Clevudine will not demonstrate any additive antiviral benefit in combination with tenofovir in the head-to-head study, the risk that Clevudine will not demonstrate superiority over Hepsera in Clevudine's ongoing Phase 3 registration study, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

Viread and Hepsera are registered trademarks of Gilead Sciences, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2008)...paign to Spread Awareness and Bring Hope to Millio...swire-USNewswire/ -- 133 million children,across t...uch as natural,disaster, civil war, and disease. S...World Orphan Week by calling attention to the need...ews Release, go to:, http://www.prnewswire.com/m...
(Date:10/9/2008)...nal Science Institute, Navigenics, Affymetrix and,...N DIEGO, Oct. 9 /- A consortium of he...ined forces in a first-of-its-kind,research study ...c testing,on people who choose to receive such scr...oping certain diseases., Sponsored by Scripps Tra...
(Date:10/8/2008)...eday Inform Treatments for Spinal Cord, Other Nerv...Newswire/ -- A protein that enables,nerve cells to...ontrolling,the developing nervous system. Research...o form among nerve cells may provide a basis for e...s to their nervous system,including spinal cord i...
(Date:10/8/2008)...am to evaluate TAXUS(R) Element(TM) Platinum Chrom..., Mass., Oct. 8 /- Boston S...d that it has completed enrollment in,the PERSEUS ...neration,TAXUS(R) Element(TM) paclitaxel-eluting c...rolled nearly 1,500 patients at 100 U.S. and,inter...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Your belly fat could be making you hungrier 17023 1Your belly fat could be making you hungrier 17023 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 1GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 3The Miracle of Funding by State and Local Pension Plans 17016 1The Miracle of Funding by State and Local Pension Plans 17016 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 1AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 3
...WIRE)--Jun 1, 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, ...mpany developing novel therapeutics to treat cance...n of two abstracts in the,2007 Annual Meeting prog...ng of the American Society of Clinical Oncology (A...or the first time full data from a,randomized Phas...
... 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences ...se 2,monotherapy trial showing that tanespimycin d... patients with metastatic melanoma,including one ...d,prior chemotherapy (within 6 weeks of initiation...on-free survival for more than,six months and 20% ...
Other Medicine Technology:OXiGENE Abstracts Published in ASCO Program 2OXiGENE Abstracts Published in ASCO Program 3OXiGENE Abstracts Published in ASCO Program 4Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 2Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 3Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 4
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...test mysteries that has been plaguing mankind is t... have finally been able to unravel the mystery wit...y scientists after a study of more than 1000 peopl...eed to be answered on a scale of 1 to 10 and the s...
...by researchers in the Institute of Preventive Medi...asionally may be beneficial in countering dementia...that people who drank wine weekly or monthly were ...ia, said that the findings are important because t...
...earchers of the Harvard Medical School, of more th...amine antagonists, i.e. anti-psychotics, for eithe... have an increased risk of breast cancer. The stud... taking dopamine antagonists and 55,000 women who ...
...ished in an online issue of Nature Medicine by res... a stunning discovery of a bold new type of vaccin...gs. The study which was carried// out on monkeys s...med and adapted in humans may signal a major new t...
Other Medicine News:Health News:The Happiness Formula.... 2
Flattened Blunt Tip, Angled; 13mm from angle to tip; 3mm "U" shape tip; overall length excluding hub 28mm; in stainless steel.
Set of Five, Long, with side port; all approximately 75mm in length; in Stainless Steel.
HYDRACLEAR is our brandname for a remarkable moisture rich element that lies throughout the interior and exterior of the ACUVUE ADVANCE Brand Contact Lenses creating a unique soft, silky feel.
The only solution for in-line digital measurement
Medicine Products: